Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

Name: Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
License: Public Domain

West China Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

immunotherapy

renal cell carcinoma (kidney cancer), immunotherapy, molecular targeted therapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 432896
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.